News | May 19, 2014

Minimally Invasive Valve Procedure Saves More Lives Than Open-Heart Surgery

Findings revealed to American College of Cardiology, The New England Journal of Medicine

May 19, 2014 — For the first time, a minimally invasive transcatheter valve — tested by Baylor Research Institute in Dallas (BRI) — has been shown to save more lives than open-heart surgery, according to new research revealed at the American College of Cardiology’s (ACC) 2014 Scientific Sessions and published in The New England Journal of Medicine.

The research is part of a clinical trial that studied the transcatheter aortic valve replacement (TAVR) procedure, which uses a wired catheter to implant a self-expanding valve device through a small incision in the leg. The procedure is used to treat patients with aortic stenosis, a condition that narrows the aortic valve, affecting blood flow.

As a principal investigator in the Medtronic CoreValve U.S. Pivotal Trial, Robert C. Stoler, M.D., FACC, FSCAI, led the study of patients at Baylor Heart and Vascular Hospital (BHVH). The hospital was one of 45 national trial sites and the only site in North Texas to participate in the research.

“This is the first time we’ve seen a transcatheter-based therapy do better than open-heart surgery patients,” Stoler said. “That really opens up a door for treating patients in the future with a far less invasive method of valve replacement.”

According to the study’s findings, patients with the TAVR CoreValve device experienced significantly improved survival ratings (85.8 percent vs. 80.9 percent) at one year, compared to participants who underwent invasive, open-heart surgery to implant replacement valves. Additionally, CoreValve patients showed better quality of life indicators at 30 days, compared with open-heart participants.

“And those results are just the tip of the iceberg,” said Stoler, adding that BRI is involved in several other studies exploring TAVR’s application to valve patients. “There are new generations of valves coming out from several different manufacturers, and we’re interested to see how those affect outcomes, including stroke.”

Future studies that will be open to patients at Baylor facilities will address those issues, in addition to exploring longevity-related questions about the valve device. Because of those continuing valve-related research efforts, Stoler said, the future is promising for aortic stenosis patients.

“If you’re a patient and you need an aortic valve replacement, you have more options now,” he said. “Transcatheter valve therapy is going to expand to a bigger patient population, and we’re seeing more patients who now have a chance to be treated with valve replacement. Plus, the new generations of valves are going to have smaller catheter sizes and fewer complications. They’re only getting better.”

In early 2014, the U.S. Food and Drug Administration (FDA) approved TAVR for treatment of patients in the extreme-risk, or inoperable, category. The successful findings of the new research presented at ACC may support FDA approval for TAVR application to high-risk patients.

For more information visit: www.BaylorScottandWhite.com

Related Content

Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
The ChordArt transcatheter mitral valve leaflet chord replacement system on X-ray, showing the anchoring sections of the artificial chord.

The ChordArt transcatheter mitral valve leaflet chord replacement system on X-ray, showing the anchoring sections of the artificial chord.

News | Heart Valve Technology| August 01, 2017
Aug.
Hitachi and West Virginia University Partner to Advance Left Ventricular Mechanical Function Evaluation
News | Cardiovascular Ultrasound| July 21, 2017
Hitachi Healthcare and the West Virginia University Heart and Vascular Institute announced the formation of a new...
Edwards Sapien 3 TAVR valve will be implanted in asymptomatic aortic stenosis patients in the EARLY TAVR Trial
Feature | Heart Valve Technology| July 14, 2017
July 14, 2017 — Morristown Medical Center, part of Atlantic Health System, has randomized the first patient in the wo
Ziosoft's PhyZiodynamics 4-D processing showing a replaced aortic valve

An example of Ziosoft's PhyZiodynamics 4-D processing showing a replaced aortic valve.

Technology | Computed Tomography (CT)| July 12, 2017
July 12, 2017 — At the 2017 annual meeting for the Society of Cardiovascular Computed Tomography (SCCT), Ziosoft show
Medtronic's CoreValve Evolut R gained FDA approval for intermediate risk patients

An illustration of the self-expanding CoreValve Evolut R TAVR valve half deployed in the aortic root.

Feature | Heart Valve Technology| July 10, 2017
The U.S. Food and Drug Administration (FDA) has cleared an additional indication to expand the use Medtronic's self-...
HAART 300 Aortic Annuloplasty Device Sees U.S. Pilot Launch, First Commercial Use
News | Annuloplasty Rings| July 05, 2017
July 5, 2017 — BioStable Science & Engineering Inc.
Novel Approach May Improve Valve Function in Some Patients

Image courtesy of Messas, et al. JACC Basic to Translational Medicine.

News | Heart Valve Technology| June 30, 2017
June 30, 2017 — Pulsed cavitation ultrasound can be used to remotely soften human degenerative calcified biosprosthet
Overlay Init